FACE IPF HEAD ON and modify disease progression by slowing lung function decline How to understand and manage limited cutaneous SSc-ILD 07/06/2026 | Author: Boehringer Ingelheim Document ID: PC-SA-102972 | Expiry Date: 06/07/2028 New PPF Guidelines How to understand and manage limited cutaneous SSc-ILD Safety Profile of OFEV The Need to Act in the Face of Progression How to identify patients with RA-ILD who can benefit from OFEV The Threat of Pulmonary Fibrosis Across A range of ILDs RELATED CONTENT Read more 1:11 The Threat of Pulmonary Fibrosis Across A range of ILDs PC-KW-100823 (January 2028 ) Watch now Opens in new tab Read more PDF How to identify patients with RA-ILD who can benefit from OFEV PC-KW-100729 (October 2026 ) Download Opens in new tab Read more PDF The Need to Act in the Face of Progression PC-KW-100734 (November 2026 ) Download Opens in new tab Read more PDF Safety Profile of OFEV PC-SA-102973 (June 2028 ) Download Opens in new tab Home OFEV How to understand and manage limited cutaneous SSc-ILD
Read more 1:11 The Threat of Pulmonary Fibrosis Across A range of ILDs PC-KW-100823 (January 2028 ) Watch now Opens in new tab
Read more PDF How to identify patients with RA-ILD who can benefit from OFEV PC-KW-100729 (October 2026 ) Download Opens in new tab
Read more PDF The Need to Act in the Face of Progression PC-KW-100734 (November 2026 ) Download Opens in new tab